Validate Gene Expression and Proteomic Signatures Predictive of Treatment for Response for Breast Cancer Patient
NCT00669773
·
clinicaltrials.gov ↗
PHASE2
Phase
UNKNOWN
Status
49
Enrollment
OTHER
Sponsor class
Conditions
Breast Cancer
Interventions
DRUG:
Adriamycin
DRUG:
Docetaxel
Sponsor
National University Hospital, Singapore